Monitoring
Patients on watchful waiting should be assessed at 6 months and then annually, provided that there are no absolute indications for surgery and symptoms do not deteriorate. Patients on pharmacological therapy should be assessed 4-12 weeks after initiating treatment to determine response to treatment and safety. Patients taking alpha blockers, anticholinergics, beta-3 adrenergic agonist, PDE5 inhibitors or combination therapy should be assessed at 4-6 weeks after drug initiation and then every 6-12 months thereafter. Patients taking 5-alpha reductase inhibitors should be assessed at 3-6 months after drug initiation and then every 6-12 months thereafter. Patients on 5-alpha reductase inhibitors should be monitored with annual DRE and PSA. Patients who underwent surgical therapy should be assessed 4-6 weeks after catheter removal to evaluate for treatment response and adverse events. Lastly, no further reassessment is necessary in patients without adverse events and with symptomatic relief.
Benign Prostatic Hyperplasia_Follow Up